A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

Clinical trial NCT06433726 · UNKNOWN

Trial details

NCT number: NCT06433726
Sponsor: Chengdu Baiyu Pharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2024-03-11
Primary completion: 2025-06-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.